Dual Immunotherapy Strategies in Metastatic NSCLC: Evidence, Safety, and Clinical Decision-Making

This episode, titled Dual Immunotherapy Strategies in Metastatic NSCLC: Evidence, Safety, and Clinical Decision-Making, features lung cancer experts discussing the following critical questions:

Other trials that have shown improvement with a dual immunotherapy regimen include CheckMate 227 and POSEIDON. What was the key safety and efficacy data from these trials?

What are your clinical considerations for determining if a patient will receive a dual immunotherapy regimen?

Led by the Dr. Dietrich, Drs. Weiss and Niu examined the phase 3 CheckMate 227 trial, which demonstrated that combining nivolumab and ipilimumab significantly improved overall survival compared with chemotherapy in patients with metastatic NSCLC, with benefits observed across PD-L1 expression levels. The POSEIDON trial similarly showed that dual immunotherapy plus chemotherapy improved progression-free and overall survival versus chemotherapy alone, while maintaining a manageable safety profile. Both trials reported immune-related adverse events consistent with known class effects, including dermatitis, colitis, pneumonitis, and endocrinopathies, which were generally reversible with prompt recognition and appropriate management.

When deciding whether to use a dual immunotherapy regimen, clinicians consider PD-L1 status, tumor histology, patient performance status, comorbidities, prior therapies, and the patient’s ability to tolerate potential immune-related toxicity. Dual immunotherapy may be favored for patients without actionable driver mutations who can tolerate the regimen and who may benefit from a chemotherapy-sparing approach or long-term durable responses. Differentiation between FDA-approved regimens involves evaluating the supporting trial data, regulatory indications, combination with chemotherapy, dosing schedules, and toxicity profiles. Multidisciplinary input, including oncology, pulmonology, and supportive care teams, is essential to optimize patient selection and manage adverse events effectively.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, Key Immunotherapy and Chemoimmunotherapy Trials Shaping Metastatic NSCLC Management,, panelists will continue their discussion on additional clinical considerations.